Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Completed · Phase 1

Conditions studied: Leukemia, Myeloid, Acute

In brief

The purpose of this study is to characterize the safety and tolerability of JNJ-63709178 and identify the recommended Phase 2 dose(s) (RP2D) and schedule for JNJ-63709178 in Part 1 and to characterize the safety and tolerability of JNJ-63709178 at the RP2D(s) in Part 2.

Key facts

Study ID

NCT02715011

Run by

Janssen Research & Development, LLC

People needed

62

Starts

2016-06-01

Expected to finish

2021-03-26

Last updated by the study team

2021-08-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A diagnosis of acute myeloid leukemia (AML) according to the World Health Organization 2008 criteria with relapsed or refractory disease and ineligible for or have exhausted standard therapeutic options
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
• Hematology laboratory parameters within the Protocol specified range
• Chemistry laboratory parameters within the Protocol specified range
• A woman of childbearing potential must have a negative highly sensitive serum (beta human chorionic gonadotropin [b-hCG]) or urine test prior to the first dose of study drug

You may not qualify if…

• Acute promyelocytic leukemia
• Active central nervous system involvement
• Prior solid organ transplantation
• Prior hematopoietic stem cell transplant within 6 months of enrollment. If the participant had an allogenic transplant there must be no apparent signs of graft versus host disease and participants must have discontinued all immunosuppressive therapies for at least 4 weeks
• Prior treatment with a CD123xCD3 bispecific agent, T cells expressing CD123 specific chimeric antigen receptor, or toxin-conjugated to CD123 antibodies; prior treatment with naked anti-CD123 monoclonal antibody is permitted

Where it is running

• Study site — Detroit, Michigan, United States
• Study site — New York, New York, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Nashville, Tennessee, United States
• Study site — Houston, Texas, United States
• Study site — Barcelona, Spain
• Study site — Madrid, Spain
• Study site — Seville, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.